Open Label Study to Assess the Pharmacokinetics of Intranasal Ketorolac Tromethamine Following Fluticasone Propionate in Healthy Subjects

This study has been completed.
Sponsor:
Information provided by:
Luitpold Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01365611
First received: June 1, 2011
Last updated: March 18, 2013
Last verified: March 2013

June 1, 2011
March 18, 2013
February 2007
May 2007   (final data collection date for primary outcome measure)
  • Cmax (the Maximum Observed Plasma Concentration of Ketorolac Tromethamine) [ Time Frame: PK parameters were determined using the following blood sampling times: pre-dose (within 10 minutes of ketorolac tromethamine administration), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 15 and 24 h post administration of study drug on Days 1 and 6 ] [ Designated as safety issue: No ]
  • Tmax (the Time to Maximum Concentration of Ketorolac Tromethamine) [ Time Frame: PK parameters were determined using the following blood sampling times: pre-dose (within 10 minutes of ketorolac tromethamine administration), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 15 and 24 h post administration of study drug on Days 1 and 6 ] [ Designated as safety issue: No ]
  • AUC 0-t (the Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Last Quantifiable Time Point Post-dose of Ketorolac Tromethamine). [ Time Frame: PK parameters were determined using the following blood sampling times: pre-dose (within 10 minutes of ketorolac tromethamine administration), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 15 and 24 h post administration of study drug on Days 1 and 6 ] [ Designated as safety issue: No ]
  • AUC Inf (the AUC From Time Zero to Infinity, Where Possible) [ Time Frame: PK parameters were determined using the following blood sampling times: pre-dose (within 10 minutes of ketorolac tromethamine administration), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 15 and 24 h post administration of study drug on Days 1 and 6 ] [ Designated as safety issue: No ]
  • t1/2z (the Terminal Half-life of Ketorolac Tromethamine, Where Possible) [ Time Frame: PK parameters were determined using the following blood sampling times: pre-dose (within 10 minutes of ketorolac tromethamine administration), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 15 and 24 h post administration of study drug on Days 1 and 6 ] [ Designated as safety issue: No ]
  • MRT (the Mean Residence Time of Ketorolac Tromethamine, Where Possible) [ Time Frame: PK parameters were determined using the following blood sampling times: pre-dose (within 10 minutes of ketorolac tromethamine administration), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 15 and 24 h post administration of study drug on Days 1 and 6 ] [ Designated as safety issue: No ]
  • Cmax (the maximum observed plasma concentration) [ Time Frame: PK parameters were determined using the following blood sampling times: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 15 and 24 h post administration of study drug on Days 1 and 6 ] [ Designated as safety issue: No ]
  • Tmax (the time to maximum concentration) [ Time Frame: PK parameters were determined using the following blood sampling times: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 15 and 24 h post administration of study drug on Days 1 and 6 ] [ Designated as safety issue: No ]
  • AUC 0-t (the area under the plasma concentration-time curve (AUC) from time zero to the last quantifiable time point post-dose. [ Time Frame: PK parameters were determined using the following blood sampling times: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 15 and 24 h post administration of study drug on Days 1 and 6 ] [ Designated as safety issue: No ]
  • AUC inf (the AUC from time zero to infinity, where possible) [ Time Frame: PK parameters were determined using the following blood sampling times: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 15 and 24 h post administration of study drug on Days 1 and 6 ] [ Designated as safety issue: No ]
  • t1/2z (the terminal half-life, where possible) [ Time Frame: PK parameters were determined using the following blood sampling times: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 15 and 24 h post administration of study drug on Days 1 and 6 ] [ Designated as safety issue: No ]
  • MRT (the mean residence time, where possible) [ Time Frame: PK parameters were determined using the following blood sampling times: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 15 and 24 h post administration of study drug on Days 1 and 6 ] [ Designated as safety issue: No ]
  • λz (the apparent plasma terminal phase rate constant, where possible) [ Time Frame: PK parameters were determined using the following blood sampling times: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 15 and 24 h post administration of study drug on Days 1 and 6 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01365611 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Open Label Study to Assess the Pharmacokinetics of Intranasal Ketorolac Tromethamine Following Fluticasone Propionate in Healthy Subjects
Open Label Study to Assess the Pharmacokinetics of Intranasal Ketorolac Tromethamine Following Multiple Doses of Fluticasone Propionate in Healthy Subjects

This was a non-randomized, open label study in healthy male and female volunteers. A single intranasal dose of 30 mg ketorolac tromethamine was administered to all subjects on Days 1 and 6; in addition, subjects received a daily intranasal dose of 200 µg fluticasone propionate on Days 2-6. Subjects remained resident in the Clinical Unit from the evening of Day 1 until the morning of Day 2 and from the evening of Day 5 until the morning of Day 7, and made ambulatory visits to the Clinical Unit on the morning of Days 3-5. A post study medical was performed within 7 days of study completion.

The objective of this study was to assess the effects of chronic administration of fluticasone propionate on the pharmacokinetics of intranasal ketorolac in healthy male and female subjects.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Healthy Subjects
  • Drug: Ketorolac tromethamine
    A single intranasal dose of 30 mg ketorolac tromethamine was administered to all subjects on Days 1 and 6.
  • Drug: Fluticasone Propionate
    Daily intranasal dose of 200 ug fluticasone propionate on Days 2-6
Experimental: Ketorolac tromethamine
Interventions:
  • Drug: Ketorolac tromethamine
  • Drug: Fluticasone Propionate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
36
March 2008
May 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female volunteers aged 18 to 60 years inclusive
  • Female subjects of child bearing potential must have had a negative urine pregnancy test prior to entry into the study and must not have been breastfeeding
  • All male subjects with female partners of child bearing potential must have consented to use a medically acceptable method of contraception (oral or implanted contraceptive hormones, intrauterine device or surgical sterilization plus condom or diaphragm with spermicidal agent) throughout the study period
  • Subject must have given signed informed consent
  • Subject was within 20% of the normal weight for his/her height and body build according to the table of "Desirable Weights for Men and Women" (Metropolitan Life Insurance Co. 1999)
  • Subject's medical history was considered normal, with no clinically significant abnormalities
  • Subject was considered to be in good health in the opinion of the Investigator as determined by a pre-study physical examination with no clinically significant abnormalities, vital signs within normal ranges and an electrocardiogram (ECG) with no clinically significant abnormalities
  • Subject's pre study clinical laboratory findings were within the normal range or if outside of the normal range were not deemed clinically significant in the opinion of the Investigator
  • Subject had bilateral patent nasal airways at screening and Day 1 as assessed by the Investigator
  • Subject had a body weight of at least 60 kg

Exclusion Criteria:

  • Subject had had a clinically significant illness in the 4 weeks before screening
  • Subject had used prescribed medications in the 3 weeks prior to dosing or over-the-counter preparations for 7 days prior to dosing, except paracetamol which was allowed up to 48 h prior to dosing. However, use of multivitamins and oral contraceptives was permitted
  • Subject had a significant history of drug/solvent abuse, or a positive drugs of abuse (DOA) test at screening
  • Subject had a history of alcohol abuse or currently drank in excess of 28 units per week (males) or 21 units per week (females)
  • Subject was a current user of tobacco or had a history of smoking in the past 5 years
  • Subject was in the opinion of the Investigator not suitable to participate in the study
  • Subject had participated in any clinical study with an investigational drug/device within 3 months prior to dosing
  • Subject had a positive result of human immunodeficiency virus (HIV) screen, hepatitis B screen or hepatitis C screen
  • Subject had had a serious adverse reaction or significant hypersensitivity to any drug
  • Subject had donated 500 mL or more of blood within the 3 months prior to screening
  • Subject had any history of co-existing nasal polyps, nonsteroidal anti-inflammatory drug (NSAID) sensitivity and asthma
  • Subject had had an allergic reaction to aspirin or other NSAIDs
  • Subject had a current upper respiratory tract infection or other respiratory tract condition that could interfere with the absorption of the nasal spray or with the assessment of adverse events (AEs)
  • Any suspicion of rhinitis medicamentosa (chronic daily use of topical decongestants)
  • Subject had used a monoamine oxidase inhibitor in the 14 days prior to study entry
  • Subject had active peptic ulcer disease, gastrointestinal bleeding or perforation, or a history of peptic ulcer disease or gastrointestinal bleeding
  • Subject had anemia due to unexplained or known gastrointestinal bleeding
  • Subject had a history of asthma or any other chronic pulmonary disorder
  • Subject had renal impairment or a risk of renal failure due to volume depletion
  • Subject had a previous history of nasal surgery
Both
18 Years to 60 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT01365611
ROX 2006-04
No
David Bregman, M.D., Ph.D., Luitpold Pharmaceuticals, Inc.
Luitpold Pharmaceuticals
Not Provided
Principal Investigator: Cyril Clarke, BSc MB BS MFPM ICON Development Solutions
Luitpold Pharmaceuticals
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP